Daniel Judge to Disease Progression
This is a "connection" page, showing publications Daniel Judge has written about Disease Progression.
Connection Strength
0.449
-
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
Score: 0.143
-
Yield of serial evaluation in at-risk family members of patients with ARVD/C. J Am Coll Cardiol. 2014 Jul 22; 64(3):293-301.
Score: 0.095
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
Score: 0.032
-
Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiol. 2017 03 01; 2(3):293-302.
Score: 0.029
-
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
Score: 0.025
-
Angiotensin II-dependent TGF-? signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014 Jan; 124(1):448-60.
Score: 0.023
-
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
Score: 0.023
-
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug; 164(2):222-228.e1.
Score: 0.021
-
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012 Feb 20; 14:17.
Score: 0.020
-
Noncanonical TGF? signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011 Apr 15; 332(6027):358-61.
Score: 0.019
-
Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011 Apr 15; 332(6027):361-5.
Score: 0.019